Li Min, Huang Tianqing, Li Xiaolan, Shi Zhiwei, Sheng Yue, Hu Mimi, Song Kui
Department of Pharmacy, The First Affiliated Hospital of Jishou University, Jishou, Hunan, 416000, People's Republic of China.
Department of Neurology, The First Affiliated Hospital of Jishou University, Jishou, Hunan, 416000, People's Republic of China.
Onco Targets Ther. 2021 Apr 15;14:2661-2672. doi: 10.2147/OTT.S297132. eCollection 2021.
Checkpoint kinase 1 (CHK1) plays an important role in DNA damage response and cell cycle progression. Thus, targeting CHK1 is an efficient strategy for cancer therapy.
The present study aimed to investigate the potential therapeutic effects of GDC-0575, a CHK1-specific inhibitor, in colitis-associated cancer (CAC) and colitis.
We established a DSS-induced acute colitis model and an azoxymethane/dextran sodium sulfate (DSS)-induced CAC model using mice and tested the effect of GDC-0575 on them. Flow cytometry and immunofluorescence were employed to investigate the infiltration of immune cells, and inflammatory cytokine expression in the colon of mice with CAC or colitis was investigated using ELISA and qPCR. We also investigated the correlation between CHK1 and CCL2/CCR2 in human colorectal cancer (CRC) tissues.
Administration of GDC-0575 significantly inhibited CHK1 expression in the colon and dramatically impaired the development of CAC and colitis in mice. Moreover, the inhibition of CHK1 expression resulted in efficient inhibition of infiltration by iNOS-positive macrophages, but had no significant effect on CD4 T cells, CD8 T cells, and myeloid-derived suppressor cells (MDSCs). Significant downregulation of TNF-α, IL-6, and IL-1β and dramatic upregulation of IL-10 were observed in the colons of both mice with CAC and colitis treated with GDC-0575. CCL2 expression was also downregulated by GDC-0575 in both mice with CAC and colitis; this was followed by the inhibition of CCR2 macrophage infiltration in the colon. Furthermore, we report a positive correlation between CHK1 expression and CCL2/CCR2 expression in the malignant tissues of patients with CRC.
Taken together, we infer that GDC-0575 impairs the development of CAC and colitis by regulating cytokine expression and inhibiting CCR2 macrophage infiltration in mice colon.
检查点激酶1(CHK1)在DNA损伤反应和细胞周期进程中发挥重要作用。因此,靶向CHK1是一种有效的癌症治疗策略。
本研究旨在探讨CHK1特异性抑制剂GDC-0575在结肠炎相关癌(CAC)和结肠炎中的潜在治疗作用。
我们使用小鼠建立了葡聚糖硫酸钠(DSS)诱导的急性结肠炎模型和氧化偶氮甲烷/葡聚糖硫酸钠(AOM/DSS)诱导的CAC模型,并测试了GDC-0575对它们的影响。采用流式细胞术和免疫荧光法研究免疫细胞浸润情况,并用酶联免疫吸附测定(ELISA)和定量聚合酶链反应(qPCR)检测CAC或结肠炎小鼠结肠中炎性细胞因子的表达。我们还研究了人结直肠癌(CRC)组织中CHK1与趋化因子配体2(CCL2)/趋化因子受体2(CCR2)之间的相关性。
给予GDC-0575可显著抑制结肠中CHK1的表达,并显著抑制小鼠CAC和结肠炎的发展。此外,抑制CHK1表达可有效抑制诱导型一氧化氮合酶(iNOS)阳性巨噬细胞的浸润,但对CD4 T细胞、CD8 T细胞和骨髓来源的抑制性细胞(MDSC)没有显著影响。在用GDC-0575治疗的CAC和结肠炎小鼠的结肠中均观察到肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)显著下调,白细胞介素-10(IL-10)显著上调。GDC-0575还下调了CAC和结肠炎小鼠结肠中的CCL2表达;随后抑制了CCR2巨噬细胞在结肠中的浸润。此外,我们报告了CRC患者恶性组织中CHK1表达与CCL2/CCR2表达之间呈正相关。
综上所述,我们推断GDC-0575通过调节细胞因子表达和抑制小鼠结肠中CCR2巨噬细胞浸润来损害CAC和结肠炎的发展。